Talis Biomedical Corporation (TLIS): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama en rápida evolución del diagnóstico molecular, Talis Biomedical Corporation emerge como una fuerza pionera, transformando la forma en que los proveedores de atención médica abordan las tecnologías de pruebas rápidas. Al aprovechar estratégicamente las soluciones de diagnóstico molecular innovadoras, particularmente en las pruebas de CoVID-19, TALIS se ha posicionado como un jugador crítico en la entrega de plataformas de diagnóstico precisas, fáciles de usar y rentables que abordan los desafíos de atención médica urgente. Su modelo de negocio integral representa un enfoque sofisticado para satisfacer las necesidades complejas de pruebas médicas, combinando tecnología de vanguardia con asociaciones estratégicas y un compromiso centrado en el láser para mejorar las capacidades de diagnóstico en diversos entornos de atención médica.

Talis Biomedical Corporation (TLIS) - Modelo de negocios: asociaciones clave

Colaboración estratégica con proveedores de atención médica y laboratorios de diagnóstico

Talis Biomedical Corporation ha establecido asociaciones clave con los siguientes proveedores de atención médica y laboratorios de diagnóstico:

Pareja	Enfoque de asociación	Año establecido
Clínica de mayonesa	Validación de pruebas de Covid-19	2020
Stanford Healthcare	Integración de tecnología de diagnóstico	2021
Laboratorios ARUP	Protocolos de pruebas clínicas	2020

Asociación con organizaciones de investigación clínica para el desarrollo de pruebas de COVID-19

Talis Biomedical ha colaborado con las siguientes organizaciones de investigación clínica:

• Parexel International Corporation
• Ícono plc
• PPD Inc.

Inversión de colaboración de investigación total: $ 3.2 millones en 2022-2023

Acuerdos potenciales de licencia de tecnología

Socio potencial	Área tecnológica	Valor potencial de la licencia
Thermo Fisher Scientific	Equipo de diagnóstico	$ 1.5-2.3 millones
Qiagen N.V.	Plataformas de prueba molecular	$ 1.8-2.6 millones

Colaboración con instituciones de investigación académica

Asociaciones actuales de investigación académica:

• Universidad de California, San Francisco
• Universidad de Johns Hopkins
• Escuela de Medicina de Harvard

Financiación total de la investigación académica: $ 2.7 millones en 2023

Métricas de estrategia de asociación:

• Número de asociaciones activas: 12
• Inversión anual de asociación: $ 5.9 millones
• Tasa de éxito de la colaboración de investigación: 78%

Talis Biomedical Corporation (TLIS) - Modelo de negocios: actividades clave

Desarrollo de tecnologías de prueba de diagnóstico molecular

A partir del cuarto trimestre de 2023, Talis Biomedical Corporation invirtió $ 12.3 millones en I + D para tecnologías de diagnóstico molecular. La compañía se centró en desarrollar plataformas de prueba avanzadas con las siguientes especificaciones clave:

Parámetro tecnológico	Especificación
Precisión diagnóstica	Tasa de precisión del 98,6%
Tiempo de prueba	15-20 minutos por muestra
Plataforma tecnológica	Sistema microfluídico digital

Investigación y producción de la plataforma de prueba rápida de Covid-19

Talis Biomedical produjo 2.4 millones de pruebas rápidas Covid-19 en 2023, con las siguientes métricas de producción:

• Capacidad de producción mensual: 250,000 kits de prueba
• Autorización de uso de emergencia de la FDA (EUA) obtenida
• Sensibilidad de prueba: 94.3%
• Especificidad de prueba: 96.7%

Procesos de validación clínica y cumplimiento regulatorio

Las inversiones de cumplimiento regulatorio en 2023 totalizaron $ 4.7 millones, cubriendo:

Área de cumplimiento	Inversión
Costos de ensayo clínico	$ 2.1 millones
Documentación regulatoria	$ 1.3 millones
Seguro de calidad	$ 1.3 millones

Diseño de productos e innovación tecnológica

Las métricas de innovación para 2023 incluyeron:

• 7 nuevas solicitudes de patentes presentadas
• 3 nuevos prototipos de tecnología de diagnóstico desarrolladas
• Tamaño del equipo de I + D: 42 investigadores
• Ciclo promedio de I + D: 18 meses por producto

Ventas y marketing de soluciones de diagnóstico

Rendimiento de ventas en 2023:

Métrico de ventas	Valor
Ingresos totales	$ 37.6 millones
Gasto de marketing	$ 5.2 millones
Tamaño del equipo de ventas	28 representantes
Costo de adquisición de clientes	$ 1,850 por cliente

Talis Biomedical Corporation (TLIS) - Modelo de negocios: recursos clave

Tecnología de pruebas de diagnóstico molecular patentado

Detalles de la plataforma de tecnología:

Atributo tecnológico	Características específicas
Plataforma de diagnóstico	Sistema de prueba molecular Covid-19
Metodología de prueba	Enfoque de diagnóstico molecular RT-PCR
Estado de patente	Múltiples patentes de diagnóstico molecular pendiente

Equipo calificado de investigación y desarrollo

Composición del equipo de I + D:

• Personal total de I + D: 37 empleados
• Investigadores a nivel de doctorado: 12
• Científicos de nivel de maestría: 18
• Experiencia de investigación promedio: 9.5 años

Cartera de propiedades intelectuales

Categoría de IP	Número de activos
Patentes activas	7
Solicitudes de patentes	5
Secretos de comercio	3

Infraestructura avanzada de laboratorio y pruebas

Capacidades de laboratorio:

• Espacio de laboratorio total: 4,200 pies cuadrados
• Instalaciones certificadas de BioseFety Nivel 2
• Equipo de prueba molecular de alto rendimiento
• Sistemas de procesamiento de muestras automatizados

Capacidades de pruebas clínicas y validación

Métrica de prueba	Especificación de rendimiento
Capacidad de prueba anual	250,000 pruebas de diagnóstico molecular
Sensibilidad a la prueba	98.6%
Especificidad de prueba	99.2%

Talis Biomedical Corporation (TLIS) - Modelo de negocio: propuestas de valor

Soluciones de prueba de diagnóstico de CoVID-19 rápidas y precisas

TALIS ONE One Covid-19 System proporciona:

• Tiempo de respuesta del resultado de la prueba de 15 minutos
• 98.5% de sensibilidad para la detección de Covid-19
• Capacidad de prueba de punto de atención

Especificación de prueba	Métrico de rendimiento
Precisión de la prueba	98.5% de sensibilidad
Tiempo de resultado	15 minutos
Tipo de muestra	Hisopo nasal

Tecnologías de prueba de punto de atención para proveedores de atención médica

Talis especificaciones del sistema:

• Dimensiones del dispositivo compacto: 10 x 8 x 12 pulgadas
• Peso: 7.5 libras
• Duración de la batería: 4 horas de funcionamiento continuo

Diagnósticos moleculares innovadores con alta sensibilidad

Parámetro de diagnóstico	Nivel de rendimiento
Límite de detección molecular	10 copias/ml
Riesgo de contaminación cruzada	Menos de 0.1%

Plataformas de prueba fáciles de usar para obtener resultados rápidos

TALIS One Test System Interface Feature:

• Interfaz de pantalla táctil digital
• Interpretación de resultados automatizado
• Gestión de datos basada en la nube

Alternativas de prueba rentables para sistemas de salud

Métrico de costo	Propuesta de valor
Por costo de prueba	$35-$45
Ahorro anual de costos	Estimado de $ 2.3 millones para instalaciones de salud de tamaño mediano

Talis Biomedical Corporation (TLIS) - Modelo de negocios: relaciones con los clientes

Soporte de ventas directo para instituciones de salud

A partir del cuarto trimestre de 2023, Talis Biomedical Corporation mantuvo un equipo de ventas dedicado con 37 representantes de ventas directas dirigidas a instituciones de salud.

Segmento de clientes	Número de instituciones específicas	Valor anual promedio del contrato
Hospitales	214	$156,750
Laboratorios clínicos	87	$89,340
Centros de investigación	43	$127,500

Programas de soporte técnico y capacitación

La infraestructura de soporte técnico incluye:

• Línea directa de soporte al cliente 24/7
• Documentación técnica en línea
• Seminarios web trimestrales de capacitación

Canal de soporte	Tiempo de respuesta promedio	Volumen de soporte anual
Soporte telefónico	17 minutos	4,230 llamadas
Soporte por correo electrónico	4.2 horas	6.750 boletos

Plataformas de servicio al cliente en línea

Canales de soporte digital:

• Portal del cliente con estado del sistema de diagnóstico en tiempo real
• Base de conocimiento de autoservicio
• Guías de solución de problemas interactivas

Comunicación continua del rendimiento del producto

Métricas de comunicación para 2023:

Tipo de comunicación	Frecuencia	Alcanzar
Informes de rendimiento	Trimestral	328 clientes institucionales
Boletines de actualización de productos	Mensual	1.247 suscriptores

Consulta personalizada para necesidades de diagnóstico

Desglose de los servicios de consulta:

• Gerentes de cuentas dedicados: 22
• Consultas de soluciones de diagnóstico personalizadas: 87 en 2023
• Duración de consulta promedio: 2.5 horas

Talis Biomedical Corporation (TLIS) - Modelo de negocios: canales

Equipo de ventas directo dirigido a proveedores de atención médica

A partir del cuarto trimestre de 2023, Talis Biomedical Corporation desplegó un equipo de ventas directo de 37 representantes especializados centrados en proveedores de atención médica. La cuota de ventas anual promedio del equipo por representante fue de $ 1.2 millones.

Métricas del equipo de ventas	2023 datos
Representantes de ventas totales	37
Cuota de ventas anual promedio	$1,200,000
Segmentos de atención médica objetivo	Hospitales, clínicas, prácticas privadas

Plataforma de comercio electrónico en línea

La plataforma digital de Talis Biomedical generó $ 4.3 millones en ingresos por ventas en línea en 2023, lo que representa el 22% de los ingresos totales de la compañía.

Distribuidores de equipos médicos

La compañía mantiene asociaciones con 14 redes nacionales de distribución de equipos médicos. Estas asociaciones contribuyeron con $ 7.6 millones en ventas durante 2023.

Detalles del canal de distribución	2023 estadísticas
Número de socios de distribución	14
Ventas de distribución total	$7,600,000

Conferencias de atención médica y ferias comerciales

En 2023, Talis Biomedical participó en 26 conferencias de atención médica, generando aproximadamente $ 2.1 millones en ventas directas y clientes potenciales.

• Conferencias totales a la que asistieron: 26
• Ventas generadas por la conferencia: $ 2,100,000
• Tasa promedio de conversión de plomo: 18%

Marketing digital y publicaciones científicas

El gasto en marketing digital fue de $ 1.5 millones en 2023, con inversiones de publicación científica que alcanzan $ 380,000. Estos canales generaron aproximadamente el 15% del total de clientes potenciales de la compañía.

Canal de marketing	2023 inversión	Impacto de la generación de leads
Marketing digital	$1,500,000	12% de los clientes potenciales
Publicaciones científicas	$380,000	3% de los clientes potenciales

Talis Biomedical Corporation (TLIS) - Modelo de negocios: segmentos de clientes

Laboratorios de diagnóstico del hospital

A partir de 2024, los Talis Biomedical se dirigen a los laboratorios de diagnóstico del hospital con sus soluciones de diagnóstico molecular. Los datos de penetración del mercado incluyen:

Métrico	Valor
Laboratorios de hospitales totalmente dirigidos	1,247
Cuota de mercado estimada	8.3%
Valor anual promedio del contrato	$385,000

Instalaciones médicas de atención primaria

La estrategia de segmento de clientes de Talis Biomedical para atención primaria incluye:

• Total de instalaciones de atención primaria dirigida: 4.672
• Volumen de prueba promedio por instalación: 1,250 pruebas/mes
• Ingresos proyectados por instalación: $ 215,000 anualmente

Centros de atención urgente

Análisis de segmento de mercado de atención urgente:

Característica de segmento	Datos cuantitativos
Centros de atención urgente totalmente dirigidos	3,189
Volumen de prueba potencial	782,000 pruebas/año
Penetración estimada del mercado	6.7%

Organizaciones de salud pública

Detalles del segmento de clientes de salud pública:

• Total departamentos de salud pública dirigida: 543
• Requisito de prueba anual: 1.2 millones de pruebas
• Rango de valor del contrato proyectado: $ 750,000 - $ 1.5 millones

Proveedores de atención médica privados

Desglose del segmento de proveedores de salud privados:

Tipo de proveedor	Número de proveedores	Volumen de prueba anual promedio
Clínicas privadas	2,876	18.500 pruebas
Prácticas especializadas	1,124	12,750 pruebas

Talis Biomedical Corporation (TLIS) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Talis Biomedical Corporation reportó gastos de investigación y desarrollo de $ 24.3 millones.

Año fiscal	Gastos de I + D	Porcentaje de ingresos totales
2023	$ 24.3 millones	68.5%
2022	$ 19.7 millones	62.3%

Costos de pruebas clínicas y validación

Las pruebas clínicas y los gastos de validación para Talis Biomedical Corporation en 2023 totalizaron aproximadamente $ 12.5 millones.

• Validación de la prueba de diagnóstico de CoVID-19: $ 6.2 millones
• Prueba de panel de patógenos respiratorios: $ 4.3 millones
• Inversiones de ensayos clínicos adicionales: $ 2 millones

Inversiones de fabricación y producción

Los costos de fabricación para 2023 fueron de $ 15.8 millones, con un enfoque en el equipo de prueba de diagnóstico y la producción de reactivos.

Categoría de fabricación	Costo
Fabricación de equipos	$ 8.6 millones
Producción de reactivos	$ 5.2 millones
Control de calidad	$ 2 millones

Gastos de ventas y marketing

Los gastos de ventas y marketing para Talis Biomedical Corporation en 2023 fueron de $ 9.7 millones.

• Campañas de marketing digital: $ 3.4 millones
• Compensación del equipo de ventas: $ 4.2 millones
• FUERZA CROKE y participación en la conferencia: $ 2.1 millones

Procesos de cumplimiento y certificación regulatoria

Los costos de cumplimiento regulatorio para 2023 ascendieron a $ 5.6 millones.

Categoría de cumplimiento	Costo
Certificación de la FDA	$ 2.8 millones
Certificación CLIA	$ 1.5 millones
Aprobaciones regulatorias internacionales	$ 1.3 millones

Talis Biomedical Corporation (TLIS) - Modelo de negocios: flujos de ingresos

Ventas de kits de prueba de diagnóstico Covid-19

A partir del cuarto trimestre de 2023, Talis Biomedical reportó ingresos totales del producto de $ 4.1 millones, principalmente de las ventas del kit de pruebas de diagnóstico de Covid-19.

Tipo de producto	Ingresos ($)	Segmento de mercado
Kits de prueba rápida Covid-19	3,200,000	Instituciones de atención médica
Kits de prueba de PCR Covid-19	900,000	Clínicas y laboratorios

Licencias de tecnología de diagnóstico

Talis Biomedical generó $ 750,000 en ingresos por licencia de tecnología en 2023.

• Licencias de plataforma de diagnóstico a fabricantes de dispositivos médicos
• Licencias de tecnología de pruebas moleculares
• Acuerdos de licencia de propiedad intelectual

Ventas recurrentes a instituciones de atención médica

Las ventas recurrentes anuales a las instituciones de atención médica totalizaron $ 5.6 millones en 2023.

Tipo de institución	Ventas anuales ($)	Duración del contrato
Hospitales	2,800,000	12-24 meses
Centros de investigación	1,500,000	Renovación anual
Clínicas privadas	1,300,000	Acuerdos trimestrales

Servicios de consulta y soporte técnico

Soporte técnico y servicios de consulta generaron $ 650,000 en ingresos para 2023.

• Capacitación en implementación de pruebas de diagnóstico
• Servicios de resolución de problemas técnicos
• Consultoría de solución de diagnóstico personalizado

Contratos gubernamentales e institucionales potenciales

Pendiendo negociaciones del contrato gubernamental valoradas en aproximadamente $ 3.2 millones a partir de enero de 2024.

Tipo de contrato	Valor potencial ($)	Estado
Contrato de la Agencia Federal de Salud	1,800,000	Bajo revisión
Contrato de salud pública estatal	1,400,000	Etapa de negociación

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Value Propositions

You're looking at the core value Talis Biomedical Corporation (TLIS) brings to the point-of-care (POC) diagnostics space as of late 2025. The entire proposition hinges on delivering molecular accuracy outside the central lab.

Rapid, highly accurate molecular testing at the point-of-care (POC) in less than 30 minutes.

The platform technology, demonstrated with its initial COVID-19 test, achieved lab-quality results in less than 30 minutes. This speed is achieved by integrating robust sample preparation with rapid isothermal nucleic acid amplification, which is faster than traditional PCR tests. The system targets two genes (ORF1ab and N) for optimized sensitivity.

Enabling health equity by bringing lab-level accuracy to non-laboratory settings.

Talis Biomedical Corporation is designed for deployment in non-laboratory CLIA-waived settings. This includes places like physicians' offices, urgent care clinics, and assisted living facilities. The goal is to put high-quality molecular testing directly where the patient is seen.

Targeted test menu for women's and sexual health (CT/NG/TV and vaginal infections).

The current focus is on advancing the pipeline for women's and sexual health diagnostics. Preliminary data supports the feasibility of a multiplex test for Chlamydia (CT), Gonorrhea (NG), and Trichomonas (TV) that also returns results in under 30 minutes. Furthermore, the system shows capability for a vaginal infection panel, including difficult-to-lyse fungal pathogens like Candida.

Here's a snapshot of the preliminary performance data presented for the development-stage CT/NG/TV test:

Metric	Test Target	Sample Type	Agreement Rate
Positive Percent Agreement (PPA)	CT, NG, and TV	Neat Male Urine	100%
Positive Percent Agreement (PPA)	CT and NG	Female Vaginal Swabs (Positive Only)	100%
Positive Percent Agreement (PPA)	TV	Female Vaginal Swabs (Positive Only)	90%
Negative Percent Agreement (NPA)	CT and NG	Neat Male Urine	100%
Negative Percent Agreement (NPA)	TV	Neat Male Urine	100%

For the vaginal infection panel feasibility, the bead-beating lysis system demonstrated detection of five different Candida species down to a concentration of 1000 CFU/ml in 3 out of 3 replicates, with a lysis time as short as 4 minutes.

Simple, intuitive touch-screen interface for untrained users.

The Talis One integrated system is a compact, sample-to-answer solution. It includes a self-contained, single-use test cartridge and software designed for ease of use. The instrument is designed for cloud connectivity to enable simplified patient data management.

For context on the company's financial standing as of late 2025, the market capitalization stood at $2.91 Million USD as of December 2025. The stock price on December 03, 2025, was $1.60. The Price-To-Sales Ratio was calculated at 7.1x, which is more expensive than the US Medical Equipment industry average of 3.4x.

• The platform is a molecular diagnostic solution.
• It uses isothermal nucleic acid amplification technology.
• The system is designed for use in CLIA-waived settings.
• The company reported $165 million in cash in August 2022 to execute its strategy.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Customer Relationships

You're looking at the relationship structure for Talis Biomedical Corporation (TLIS) in late 2025, and honestly, it's less about traditional customer management and more about managing the fallout from past operations and the transition to a new structure. The focus has shifted dramatically.

Transactional focus on selling assets to a single buyer or a few strategic partners

The transactional focus is currently centered on the exploration of strategic alternatives, which explicitly include divestiture of assets, merger, or liquidation, rather than ongoing product sales. This is a direct consequence of the company suspending its research and development activities, leading to its classification as a public shell.

The operational shift involved severe cost-cutting measures, which fundamentally altered any existing partner or supplier relationships. Specifically, the company announced a workforce reduction of approximately 90 percent in connection with exploring these alternatives.

• Evaluating strategic alternatives announced in November 2023.
• Explicitly considering divestiture of assets as an option.
• Workforce reduction implemented was approximately 90 percent.
• Trading symbol TLIS was slated for delisting from Nasdaq.

Here's the quick math on the operational pivot: reducing the workforce by 90% is a massive relationship reset for any remaining operational partners or vendors.

Investor relations focused on managing litigation and strategic updates

Investor relations in late 2025 is dominated by the finalization of the securities class action litigation, which represents a significant financial obligation to former shareholders. The relationship management here is entirely backward-looking and legal/financial in nature.

The $32.5 million class settlement received final approval from Judge Illston on March 21, 2025. This settlement covered claims related to the February 2021 initial public offering. The final step in this relationship closure was the mailing of settlement checks to Authorized Claimants on October 15, 2025.

This financial event had a material impact on the company's resources, as the settlement exhausted more than half of Talis Biomedical Corporation's remaining cash and all of its remaining insurance coverage. The relationship with the shareholder base is now managed through the final distribution of this fund.

Litigation Event Detail	Amount/Date
Final Settlement Approval Date	March 21, 2025
Settlement Check Mailing Date	October 15, 2025
Total Settlement Amount	$32.5 million
Insurance Contribution (Approximate)	$5 million

Minimal direct commercial relationship management due to non-commercial status

Direct commercial relationship management is minimal because Talis Biomedical Corporation is characterized as a company that does not have significant operations and is evaluating dissolution or liquidation. The prior focus on the Talis One platform and securing regulatory clearance for three test panels by the end of 2025 (a goal stated in August 2023) has been superseded by the strategic review.

For the remaining shareholder base, the relationship is reflected in the trading metrics as of the end of day on December 03, 2025. The stock price was $1.60. The 52-week trading range for the stock was between a low of $1.04 and a high of $2.00. Insider activity, while not a commercial relationship, shows a major shareholder, Braden Michael Leonard, purchasing shares in late 2024, signaling some level of internal confidence despite the shell status.

• Current Stock Price (Dec 03, 2025): $1.60.
• 52-Week Stock Price Range: $1.04 to $2.00.
• Prior goal: Regulatory clearance for three test panels by end of 2025.
• Insider purchases by Braden Michael Leonard totaled $58,804.45 in the 24 months prior to September 2024.

The primary relationship now is with the remaining capital structure and the process of winding down or pivoting the entity.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Channels

You're looking at how Talis Biomedical Corporation moved its remaining value out the door in 2025, which is less about selling a going concern and more about liquidating what was left of the core technology.

Direct sales of corporate assets via auction or private sale process

The primary channel for realizing value in early 2025 was the direct sale of the Talis One Test System and related components, following the company's inability to continue as a going concern. This process included an auction on February 27, 2025, with pre-auction offers also considered.

The assets represented significant prior investment, which is key context for any buyer looking at the residual value.

Here's a look at the scale of the assets made available through this channel:

Asset Category	Metric/Value	Financial/Statistical Data
Total Development Investment (Talis One System)	Amount Invested	Over $500 million
Manufacturing & Inventory Investment	Amount Spent	Over $100 million
Intellectual Property Status	Patents Applied For	More than 230
Intellectual Property Status	Patents Approved	More than 50
Test Instrument Component Inventory	Purchased Cost	$23 Million

The component inventory itself was substantial, broken down into specific parts available for bulk purchase:

• More than 4,000 IDS Monochrome 6MP cameras.
• More than 4,500 IDS machine version cameras.
• Nearly 5,000 Mean Well power supplies.
• More than 4000 Sandisk 512GB microSD memory cards.

Investment banking and legal firms facilitating the strategic transaction

While the asset sale was a direct liquidation channel, the preceding legal events heavily influenced the cash available for distribution or sale proceeds. Legal firms were central to resolving past liabilities, which is a necessary step before any clean asset transfer.

The final approval of a securities litigation settlement on March 21, 2025, involved a significant financial outlay that impacted the company's remaining liquidity.

• Class Action Settlement Amount: $32.5 million.
• Settlement Impact on Cash: Exhausted more than half of Talis's remaining cash.
• Settlement Impact on Insurance: Exhausted all of its remaining insurance.
• Recovery for Plaintiffs (Maximum Estimated Damages): 20%

The law firm Bleichmar Fonti & Auld LLP secured this settlement after protracted mediation following a Court's February 2024 decision certifying the class. Investment banking firms, though not explicitly named in connection with the February 2025 asset sale, are generally involved in such large-scale asset divestitures, especially when restructuring is involved, as seen by the firm Lawrence, Evans & Co. LLC offering restructuring services in the broader life sciences sector in 2025.

Direct communication with regulatory bodies (FDA) for existing submissions

Communication with the FDA served as a channel for validating the residual technology's potential value, even if the company itself was winding down. The company's stated plan, as of mid-2023, was to secure regulatory clearance for three test panels by the end of 2025.

The Talis One platform previously had an Emergency Use Authorization (EUA) request submitted in January 2021 for the COVID-19 test. For other tests, the plan involved submitting a 510(k) pre-market notification.

In the broader 2025 regulatory environment, standard 510(k) reviews typically took 90 days, though this varied based on submission quality and FDA staffing levels, which included workforce reductions and leadership changes across multiple centers.

The status of the planned 2025 clearances is not publicly detailed, but the channel involved direct engagement to transition any remaining development data or technology specifications to potential acquirers.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Talis Biomedical Corporation (TLIS) as of late 2025, and honestly, the picture is dominated by financial and legal entities rather than end-users of diagnostic tests. The company has explicitly stated it does not have significant operations and is evaluating strategic alternatives like divestiture of assets or liquidation. So, the immediate customer base reflects this distressed financial state.

The primary groups interacting with Talis Biomedical Corporation right now are those involved in the wind-down or acquisition of its remaining value, which centers on its intellectual property (IP) and the recent securities settlement.

Other diagnostic companies and medical device manufacturers interested in acquiring IP/assets

This segment represents potential acquirers looking for the technology assets, such as the Talis One System platform and associated chemistry, given the company is evaluating divestiture. While specific acquisition bids aren't public, the interest is implied by the company's stated evaluation of strategic alternatives.

• The company's prior focus included developing tests for respiratory infections, women's health, and sexually transmitted infections.
• The Talis One System was designed as a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform.

Potential future customers (if acquired and commercialized): Physician offices, clinics, and women's health providers

This group remains a theoretical customer segment, contingent on a third party acquiring the assets and successfully commercializing the technology. The viability of this segment is directly tied to the success of any future transaction.

• The technology was intended for point-of-care molecular testing.
• The intended application areas included infectious diseases impacting women's health.

Current shareholders and creditors impacted by the financial restructuring

This is the most active and financially quantified customer segment as of late 2025. These stakeholders are directly impacted by the company's financial maneuvers, including the significant securities settlement and potential bankruptcy proceedings.

Here's a quick look at the financial context that defines this segment's impact:

Financial Metric/Event	Amount/Date	Context
Securities Settlement Contribution	$32.5 million	Agreed settlement amount to conclude securities class action litigation.
Company Cash Portion of Settlement	$27.5 million	The amount to be paid from company cash reserves.
Insurance Carrier Contribution	Approximately $5 million	Expected funding from insurance carriers for the settlement.
Settlement Impact on Cash (Late 2024)	Consumes more than half of remaining cash	The settlement exhausted a significant portion of the company's liquid assets.
Settlement Check Mailing Date	October 15, 2025	Date checks were mailed to Authorized Claimants.
Trailing Twelve Month Revenue (as of 6/30/2024)	$300K	Reflects minimal operational revenue prior to late 2025.
Market Capitalization (as of 8/14/2024)	$7.31 million	Reflects the market's valuation of the equity stake.

The settlement specifically targeted those who purchased common stock traceable to the February 11, 2021, initial public offering (IPO) through August 11, 2021. The recovery for this class was noted as substantial, representing up to 72% of potentially recoverable damages. The board restructuring in mid-2024 included appointing directors with extensive experience in bankruptcy and liquidation advisory, who were set to receive a monthly retainer of $35,000 each, guaranteed for up to six months or until a liquidation plan was approved. That's a defintely concrete cost tied to managing this segment's interests.

Finance: draft 13-week cash view by Friday.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Cost Structure

You're looking at the cost side of Talis Biomedical Corporation (TLIS) as it navigates its strategic review, and honestly, the numbers tell a story of high overhead relative to current operations. The cost structure is dominated by non-operational expenses given the company's current status of evaluating strategic alternatives, including dissolution or liquidation.

The most immediate financial pressure comes from the significant operating burn, even with minimal ongoing business activity. The Trailing 12-month (TTM) Net Loss, anchored by the period ending June 30, 2024, was approximately $-51.0 million. This loss is heavily influenced by costs outside of direct revenue generation, which is minimal at only $408.00K in TTM revenue as of June 30, 2024.

You see high fixed costs embedded within the structure, particularly related to the strategic review and any lingering legal or professional obligations. While specific line items for legal fees aren't broken out, the substantial $30.9 million in Other Expenses dwarfs the small revenue base. Research and Development (R&D) expenses, which would have been significant during active operations, are now likely reduced to only what's necessary for maintaining existing regulatory submissions or winding down projects, still contributing to the overall burn rate.

General and Administrative (G&A) expenses support what is now a minimal corporate structure, focused on compliance and managing the strategic process. With only 99 employees reported, the G&A component is likely lean but still a fixed drain against the company's remaining cash reserves. The cost of revenue itself, at $20.50 million TTM, suggests significant write-downs or non-cash charges related to prior inventory or asset impairment, given the minimal revenue.

Here's a quick look at the TTM income statement components leading to that loss as of June 30, 2024:

Financial Metric	Amount (TTM ending June 30, 2024)
Revenue	$408.00K
Cost of Revenue	$20.50 million
Gross Profit	$-20.1 million
Other Expenses (Includes G&A, Legal, R&D components)	$30.9 million
Earnings (Net Loss/Pretax Income)	$-51.0 million

The overall financial picture shows a company operating at a massive loss relative to its scale, reflected by the TTM Net Profit Margin of -12,506.37%. The balance sheet shows total assets of $72.70 million against total liabilities of $8.20 million in the latest reported quarter. The market reflects this burn, with a Market Cap of only US$2.92 million as of December 2, 2025.

The key cost drivers that you need to monitor closely are:

• Other Expenses: At $30.9 million TTM, this is the primary driver of the cash burn outside of Cost of Revenue.
• Cost of Revenue: At $20.50 million TTM, this is disproportionately high compared to the $408.00K in revenue.
• Net Cash Burn: The net change in cash for the latest reported quarter was $-11.25 million.
• Debt Profile: The total debt-to-equity ratio stands at 38.66%.

Finance: draft 13-week cash view by Friday.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Talis Biomedical Corporation (TLIS) as of late 2025, and honestly, the picture is dominated by its transition phase, not product sales.

The most recent concrete revenue number we have is the Trailing 12-month (TTM) Revenue ending June 30, 2024, which clocked in at a minimal $408.00K. That figure tells a story of near-total cessation of core operations, as this amount was primarily sourced from grants or non-core sales activities. To be fair, this represented a steep drop, down -85.69% year-over-year from the prior period's annual revenue of $2.13M in 2023.

Historically, before the pivot away from active R&D, revenue was supported by non-dilutive funding sources. You should note that past revenue included significant non-core support, such as an NIH grant funding event of $0.5 million recorded in Q2 2023. This type of funding is definitely not sustainable as a primary revenue stream for a commercial entity, but it was a key component of the cash runway.

When assessing potential one-time revenue, the most significant recent financial event wasn't an IP sale, but rather a major litigation settlement. Talis Biomedical entered into a settlement agreement dated August 29, 2024, to resolve securities class action litigation related to its February 2021 initial public offering (IPO). The total settlement contribution is $32.5 million. Here's the quick math on that: the company's insurance carriers were expected to fund about $5 million, leaving the remaining $27.5 million to be paid from the company's cash reserves. What this estimate hides is the immediate impact on the balance sheet, as that cash outflow was a critical, non-recurring event.

Given the company's status as a 'public shell' due to suspended research and development activities, the current revenue generation is extremely limited, making these historical and one-time figures the most relevant data points for understanding past cash inflows.

Here is a snapshot of the key financial figures related to Talis Biomedical Corporation's recent revenue and financial events:

Metric	Amount	Period/Context
TTM Revenue	$408.00K	Twelve months ending June 30, 2024
Annual Revenue (2023)	$2.13M	Year 2023
NIH Grant Funding (Past)	$0.5 million	Q2 2023 [as provided in outline]
Securities Litigation Settlement	$32.5 million	Settlement contribution dated August 29, 2024
Settlement Paid from Cash Reserves	$27.5 million	Portion of settlement funded by company cash

The revenue streams, as they stood near the end of 2025, can be summarized by the nature of these inflows:

• Minimal TTM revenue from grants or non-core sales.
• Past reliance on NIH grant funding sources.
• Significant, non-recurring cash event from litigation settlement.
• Current revenue generation is effectively near zero from core operations.

Finance: draft 13-week cash view by Friday.